Venus Remedies Partners with Infex Therapeutics for Innovative Inhibitor

Venus Remedies has partnered with UK's Infex Therapeutics to develop MET-X, a metallo-beta-lactamase inhibitor aimed at combating drug-resistant gram-negative bacteria. The partnership focuses on clinical trials in India, targeting meropenem-resistant infections, with Venus leading development, registration, and commercialization efforts domestically.

Venus Remedies announced a strategic partnership with UK-based Infex Therapeutics on Tuesday to develop MET-X, a groundbreaking metallo-beta-lactamase inhibitor targeting drug-resistant gram-negative bacteria.

The firms have signed an exclusive license agreement authorizing Venus Remedies to lead clinical development, registration, and commercialization of MET-X in India. The initial phase will focus on integrating MET-X with meropenem, with Venus retaining exclusive marketing rights domestically.

India confronts a significant challenge from MBL-producing pathogens in hospitals, with meropenem resistance reaching up to 87%. No approved MBL inhibitors exist in the region. This collaboration marks a significant advancement in bolstering Venus's antibiotic solutions, with market release anticipated by 2031 pending regulatory approvals.

(With inputs from agencies.)